The Oxford Club’s Chief Income Strategist Marc Lichtenfeld closed out his AbbVie recommendation for a whopping 2,381% gain on the highest partial closeout in just 10 months – his biggest win yet.
Now Marc is eyeing another, BIGGER trade with 3,000% potential…
And to make sure NO ONE misses his next big play…
He’s giving away the farm.
— RECOMMENDED —
Wall Street legend Marc Chaikin is unveiling a new cash vehicle 50 years in the making… making his biggest new prediction in 50 years… and explaining how it could double or triple your money if you move your cash immediately.
- 1 What Is Marc Lichtenfeld’s drug royalty company with 3,000% potential?
- 2 Few words about Marc Lichtenfeld
- 3 What Is Penny Options Trader?
- 4 What’s Included with your Penny Options Trader Subscription?
- 4.1 Marc Lichtenfeld’s Special Report
- 4.2 A FREE Extra Year
- 4.3 An Average of Two to Three NEW Penny Options Recommendations per Month
- 4.4 Password-Protected Access to the Penny Options Trader Website
- 4.5 Weekly Email Updates
- 4.6 Access to Marc Lichtenfeld’s Member Services Team
- 4.7 Special Bonus Report No. 1: “The Genesis Cure: How to Profit From the Biggest Medical Breakthrough in History.”
- 4.8 SPECIAL JUST-ADDED BONUS REPORT No. 2: “The Safer Painkiller: How to Capture a Massive Profit on the Next Biotech Blockbuster”
- 5 Penny Options Trader Subscription Fee
- 6 Penny Options Trader Refund Policy
What Is Marc Lichtenfeld’s drug royalty company with 3,000% potential?
If you missed out on Marc Lichtenfeld’s millionaire-minting 907% win on AbbVie…
Today, you have one more chance at building a retirement fortune. Marc discovered a play that could be his biggest ever… and make you a LOT richer one year from today.
Marc Lichtenfeld found a small drug royalty company that has inked deals with the biggest players in the pharmaceutical industry, including Pfizer, Merck, Eli Lilly, Novartis and more.
It could pull in as much as $5.8 billion, blasting it 3,000% higher.
That’s why Marc Lichtenfeld is offering a free bonus year of Penny Options Trader, valued at $4,900, when you purchase a subscription today.
When you join his service, you’ll receive a copy of “How to Achieve Biotech Royalty Riches in One Year” INSTANTLY in your inbox.
You’ll get the name of the drug royalty company…
Detailed instructions on how to set yourself up for a potential 3,000% win…
Special techniques for decreasing your risk as much as possible…
And a whole lot more.
Marc Lichtenfeld is backing up his 3,000% goal with a special guarantee.
This is his way of helping Main Street folks catch up on their retirement savings and live in comfort in their golden years – without worrying about money every moment.
With your free bonus year of Penny Options Trader,Marc Lichtenfeld will be by your side every step of the way, guiding you to the biggest potential win you’ve ever seen.
Few words about Marc Lichtenfeld
Marc Lichtenfeld is The Oxford Club’s Chief Income Strategist. He has worked as a trader, senior analyst and fund manager, outperforming the S&P 500 and, thanks to his expertise in the biotech sector, the S&P Healthcare Index by a wide margin.
He is an editor of the VIP services Penny Options Trader and Oxford Bond Advantage and Predictive Profits and . Marc also serves as Senior Editor for The Oxford Income Letter. He guides his monthly newsletter’s investment strategies with his “10-11-12 System,” detailed in his book, Get Rich With Dividends: A Proven System for Double-Digit Returns.
A regular on CNBC, Marc has also appeared on Fox Business, Bloomberg radio and countless radio programs through the country. He currently hosts his own weekly broadcast, the Get Rich With Dividends radio show. Additionally, he has written for The Wall Street Journal,Barrons, US News & World Report and others. He is also a regular contributor to Investment Uand Wealthy Retirement.
— RECOMMENDED —
Wealth has evaporated. Companies are announcing salary freezes and unpaid furloughs. The price of everything keeps climbing while the values of our most precious assets, like our homes and investment accounts, are depreciating. There’s a strange reason why, but Wall Street won’t tell you about it.
What Is Penny Options Trader?
Chief Income Strategist Marc Lichtenfeld has identified the secret behind the majority of his triple-digit wins… He calls them “penny options” because they allow you to control shares of some of the world’s most profitable companies for $5 or less… And they give you the chance to see significant profits in a short period of time.
What’s Included with your Penny Options Trader Subscription?
Here’s everything you’ll get with your subscription…
Marc Lichtenfeld’s Special Report
Get all the details on what’s potentially the biggest recommendation of Marc Lichtenfeld’s career in the special report “How to Achieve Biotech Royalty Riches in One Year.”
A FREE Extra Year
You’ll get a total of two years of Penny Options Trader.
An Average of Two to Three NEW Penny Options Recommendations per Month
That’s a total of up to 36 explosive profit opportunities each year… and up to 72 over the course of your two-year subscription.
Password-Protected Access to the Penny Options Trader Website
Weekly Email Updates
You’ll always know what’s going on with Marc Lichtenfeld’s drug royalty play… and all the fast-moving positions in Penny Options Trader model portfolio.
Access to Marc Lichtenfeld’s Member Services Team
Any answers you need about your subscription are just a phone call away.
Plus, you’ll get a copy of…
Special Bonus Report No. 1: “The Genesis Cure: How to Profit From the Biggest Medical Breakthrough in History.”
Inside, you’ll learn about a technology so powerful, it can edit human DNA… giving it the potential to wipe out up to 4,800 diseases and take over a $1 trillion market.
This could hand you 2,907% gains in the next decade if you get the details now.
People have paid $4,000 to subscribe and access this report… but Marc Lichtenfeld is giving it to you for free today.
So you’ll have TWO opportunities to make a fortune.
And that’s not all…
SPECIAL JUST-ADDED BONUS REPORT No. 2: “The Safer Painkiller: How to Capture a Massive Profit on the Next Biotech Blockbuster”
Inside, you’ll find the story (and ticker symbol) of a small company waging war on the opioid crisis. Its patented painkiller is nearly impossible to abuse, so it’s far safer for people who truly need help with pain.
With bans on OxyContin spreading like wildfire, this company’s less addictive painkiller is set to take over the soon-to-be $28.8 billion painkiller market.
This opportunity could multiply your money tenfold.
— RECOMMENDED —
It doesn’t matter if you have money in the markets right now, or you’re waiting on the sidelines. The short period we’re about to enter could have the power to make – or destroy – fortunes. And what you do in the coming days could determine your wealth for the next decade. Here’s what’s happening and how to prepare.
Penny Options Trader Subscription Fee
When you become a Penny Options Trader subscriber today, you’ll also save 67%.
The retail price of Penny Options Trader is $4,900. But todauy, you’ll get a 67% discount and pay just $1,597.
And then, you’ll get a second year absolutely free.
That’s $9,800 of value for just $1,597.
Penny Options Trader Refund Policy
All sales are final.
However, in case you do subscribe, Marc Lichtenfeld is offering a personal, ironclad, double-fortified guarantee.
And as a thank you for signing up for his service, you can keep your special reports. No hard feelings.